Introduction {#sec1}
============

Many abrupt adjustments in the delivery of medical care became necessary owing to the unexpected emergence of the coronavirus disease 2019 pandemic in early 2020. To ensure social distancing and the concomitant requirements for personal protective equipment, practitioners have had to make a myriad of adjustments to continue providing subcutaneous allergen immunotherapy (SCIT). In many practices, SCIT was stopped or administration intervals have been increased, whereas other practices have transitioned some patients to the sublingual administration route.[@bib1]

Although many locations have recently eased lockdown requirements, this led to a rise in cases in several states, resulting in further lockdowns. Thus, it might very well still take months before our daily routine shall come close to normal again. Learning from historical lessons, the H1N1 influenza "Spanish flu" pandemic lasted 15 months and killed 50 million people. It comprised the following 3 waves: the first (milder) one was in winter-spring 1918; the second wave, in September 1918, was disastrous and deadly, because it coincided with the massive troop gathering and transport of soldiers for World War I and an apparent aggressive mutation of the virus; and the last wave, beginning in 1919, had less severity. Finally, the virus resolved on the development of herd immunity, the ending of the war, and possibly a favorable mutation.

Although prevention of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical, it is also important that other health concerns are addressed to limit preventable emergencies. Maintaining good health appears to reduce the risk of severe COVID-19 disease. In the context of allergic diseases, SCIT has been reported to reduce symptoms and medication requirements in allergic rhinitis, conjunctivitis, and in patients with immunoglobulin E--dependent asthma, improving the quality of life. Moreover, a case could be made that patients with an allergy might experience some ancillary immunologic benefit in battling an infectious pathogen by being on an effective SCIT dose. Immunotherapy restores the function of dendritic cells and augments the number of active T~H~1 cells, both enhance innate immunity, which could be important at the start of a SARS-COV-2 infection whose initial mechanism is innate immune suppression, a theory that might be interesting to explore.[@bib2]

For SCIT to be effective, an optimal target monthly maintenance dose has to be administered. The extended spacing interval of injections, although acceptable from a safety point of view, may result in a diminution of therapeutic efficacy. Thus, as soon as the risk for SARS-CoV-2 transmission and infection can be reduced to levels considered safe by health authorities, it behooves the allergist to return to a maintenance immunotherapy schedule known to be effective.

At this moment, there are no data from controlled trials on dose adjustment after gaps in administration. The intention of this article is to review the limited data available and discuss what is needed to answer pressing questions related to resuming SCIT after gaps in therapy.

Published Data Related to Gaps in Subcutaneous Allergen Immunotherapy Administration {#sec2}
====================================================================================

Dose Adjustment Schedules {#sec2.1}
-------------------------

In an online supplement to the Practice Parameters on Allergen Immunotherapy (third update), the authors propose a schedule on how to dose-adjust after a gap in SCIT administration. The schedule is based on the time elapsed since the missed dose.

Tangentially, the focused practice parameter update on sublingual immunotherapy recommends restarting the tablet for sublingual immunotherapy in-office after interruptions of more than 7 days. This is recommendable given anaphylaxis has been reported after the first tablet, be it rarely.[@bib3]

The largest amount of data available comes from the collective experience of more than a thousand allergy specialists. An online survey of the American Academy of Allergy, Asthma, and Immunology (AAAAI) membership was conducted and reported in 2012.[@bib4] Shortly afterward, almost 80% of responders reported dose-adjusting based on the date of the last administered dose. Most reduced the dose a certain number of steps back, others reduced a percentage, and a few reduced a certain volume. In the online supplement, we present dose adjustment schedules with one ([Table e1](#tbl1){ref-type="table"}) based on the most frequently used solutions according to the survey and others either used by large allergy practices ([eTable 2](#tbl2){ref-type="table"}, [eTable 3](#tbl3){ref-type="table"}, [eTable 4](#tbl4){ref-type="table"}, [eTable 5](#tbl5){ref-type="table"}-[eTable 3](#tbl3){ref-type="table"}, [eTable 4](#tbl4){ref-type="table"}, [eTable 5](#tbl5){ref-type="table"}) or proposed by the guidelines ([eTable 6](#tbl6){ref-type="table"}, [eTable 7](#tbl7){ref-type="table"} and [e7](#tbl7){ref-type="table"}).

Safety Reports Related to Gaps {#sec2.2}
------------------------------

The AAAAI and the American College of Allergy Asthma and Immunology Immunotherapy surveillance study started in 2008. Members submit data annually regarding SCIT-related systemic reactions and their severity. In the last update, the investigators gave a detailed description of a total of 7 fatal reactions since 2008 (1:9.1 million injection visits). Although not specifically queried for nonfatal reactions, there were no reports of fatal reactions occurring owing to a gap in therapy.[@bib5] As discussed below, the issue of gaps in therapy will be more extensively queried in this year\'s upcoming surveillance survey.

Special Considerations {#sec3}
======================

Allergen immunotherapy is still an art, and it might require extra precautions in patients who could be at higher risk for life-threatening systemic reactions. Patients with higher risk may include those with the following[@bib5]: (1) history of anaphylaxis or mast cell disorder; (2) moderate to severe asthma; (3) high sensitization pattern or systemic reaction during skin prick testing; (4) systemic reactions to previous SCIT administration; and (5) patients receiving SCIT during peak pollen season for an allergen to which they are highly sensitized. Thus, the personal background of the patient should be taken into consideration when choosing a dose adjustment schedule after a gap in therapy; pediatric age could need extra caution.

Future {#sec4}
======

There is no consensus or firm evidence suggesting which dose adjustment strategy is superior after a gap in therapy. In addition, it is unclear whether some patients may tolerate longer gaps in therapy than previously allowed, both in terms of efficacy and safety. Understanding the consequences and developing optimal strategies for dose adjustment after gaps in therapy has become paramount during the COVID-19 pandemic. Thus, the AAAAI Immunotherapy, Allergen Standardization, and Allergy Diagnostics Committee are evaluating outcomes related to various dose adjustment strategies for gaps in therapy. A prospective, randomized single-center trial evaluating outcomes for 2 different dose adjustment schedules is underway. In addition, we are gathering data using the immunotherapy surveillance study. We would like to invite colleagues to join us and submit their data regarding gaps in therapy to the surveillance study (<https://tinyurl.com/AITAnnualSurvey>).

Supplementary Data {#appsec1}
==================

eTable 1Empirical Dose Adjustment Schedule after Gaps in SCIT Administration Based on Mean Replies From the AAAAI Members\' Survey (Aqueous Extracts)All patients\
Intuitively, highly sensitive patients[a](#tbl1fna){ref-type="table-fn"} might need special caution and more drastic dose reduction after gapsDose increase phaseDose adjustment actions to be taken\<2 wk since the last doseIncrease normally≥2-3 wkRepeat the last dose≥3-4 wkReduce 1 dose≥4-5 wkReduce 2 doses90 dRestart SCIT: from bottle 1, first doseMaintenance phase\<5 wk since the last doseApply normally≥5-7 wkReduce by 25%≥7-11 wkReduce 1 dose/Reduce by 45%≥8-15 wkReduce 2 doses/Reduce by 55%≥3-4 moRestart SCIT: from bottle 1, first dose[^1][^2]eTable 2Johns Hopkins Division of Allergy and Clinical Immunology Dose Adjustment Scenarios for Standard SCIT Dose Modifications Owing to Missed InjectionsScenario A: missed build-up visit. Based on time elapsed since the last dose.1-2 wk since the last doseContinue schedule2-3 wk (15-21 d)Repeat the previous dose3-5 wk (22-35 d)Decrease by 1 dose5-6 wk (36-42 d)Decrease by 2 doses\>9 wkNotify allergist for instructionsScenario B: build-up schedule completed(Once final dose has been reached)Repeat last dose in 2 wk then,Repeat last dose in 3 wk then,Repeat last dose in 4 wk then,Continue maintenance dose every 4 wkScenario C: missed maintenance visit4-6 wk (42 d) since the last doseContinue schedule6-7 wk (43-56 d)Decrease by 1 dose5-6 wk (57-63 d)Decrease by 2 doses\>9 wkNotify allergist for instructions[^3]eTable 3Schedule Used by Allergy PartnersSchedule for missed injections for the build-upTime elapsed since the last dose2-14 dContinue increasing per schedule15-21 dRepeat the last dose, then increase per scheduleMore than 21 dReduce the dose by 1 step for each week over 3 wk, then increase per scheduleMore than 63 dAsk physicianSchedule for missed injections for maintenanceTime elapsed since the last dose0-35 dContinue the maintenance doseMore than 35 dReduce the dose by 1 step for each wk over 5 wk, then increase per scheduleMore than 91 dAsk physicianSchedule for refillsFirst dose from refillReduce to 1/3 of the maintenance doseSecond dose from refillReduce to 2/3 of the maintenance doseThird dose from refillBack to usual dose, reset phase to maintenanceeTable 4Dose Adjustment Schedule for Gaps in SCIT Administration, University of CincinnatiFor lapses in therapy in the 1:10,000, 1:1000, and 1:100 vials, adjust the dose as follows:Weeks overdue1 wk overdueRepeat the last dose2 wk overdueDecrease by 1 dose3 wk overdueDecrease by 2 doses4 wk overdueAsk MDFor lapses in therapy in the 1:10 vial, adjust the dose as follows:Wk overdue2 wk overdueReduce by 50%3 wk overdueStart at the beginning of vial4 wk overdueAsk MDFor lapses in therapy in the 1:1 vial, adjust the dose as follows:Weeks overdue1-2 wk overdueRepeat the last dose3-4 wk overdueDecrease by 1 dose4-6 wk overdueDecrease by 2 doses\>6 wk overdueAsk MD[^4][^5]eTable 5Dose Adjustment Schedule for Gaps in SCIT Administration, Northwestern UniversityImmunotherapy dose adjustments for lapses in SCIT during the build-up phaseReview IT chart for past reactions10 d overdueNo adjustment2 wk overdueIf no history of reaction: repeat dose\
If the history of reaction: decrease by 0.05 mL3 wk overdueDecrease by 0.10 mL4 wk overdueDecrease by 0.15 mLFor lapses in allergen immunotherapy during the maintenance phase:Weeks overdue2 wk overdueRepeat dose3 wk overdueDecrease by 0.05 mL4 wk overdueDecrease by 0.10 mL2 months overdueDecrease by 0.05 for each week missed after 2 wk3 months overdueWill need to discuss compliance with the patient and attending before stopping IT or restart at 1:1000 of 0.05 mL[^6]eTable 6Practice Parameters (Third Update) of Online Repository Proposed Schedule ([eTable 5](#tbl5){ref-type="table"})Build-up phase for weekly or biweekly injectionsModify dosage accordingly to time interval since missed injectionUp to 7 d[a](#tbl6fna){ref-type="table-fn"}Continue as scheduled8-13 d after missed scheduled injectionRepeat the previous dose[b](#tbl6fnb){ref-type="table-fn"}14-21 d after missed scheduled injectionReduce the dose by 25%[b](#tbl6fnb){ref-type="table-fn"}21-28 d after missed scheduled injectionReduce the previous dose by 50%[b](#tbl6fnb){ref-type="table-fn"}A similar dose reduction protocol should be developed for gaps in maintenance immunotherapy.[^7][^8]eTable 7Dose Adjustment Schedule, Mexican Guidelines on Immunotherapy 2019Prolonged interval between doses (aqueous extracts)[a](#tbl7fna){ref-type="table-fn"}\
Up-dosing phase. Time since last SCIT injection. ○ \< 2 wkIncrease normally ○ 2-3 wkRepeat the last dose ○ 3-4 wkDecrease by 1 dose ○ 4-5 wkDecrease by 2 doses ○ 6-8 wkReboot from vial 1Maintenance phase. Time since last SCIT injection. ○ \< 5 wkAdminister normally ○ 5-6 wkDecrease by 1 dose ○ 6-8 wkDecrease by 2 doses or 50% ○ 2-3 moStart vial from 0.05 mL ○ 3-4 moStart from previous vial 0.05 mL ○ \> 4 moReboot from vial 1Prolonged interval between doses (allergoid or adsorbed extracts)[b](#tbl7fnb){ref-type="table-fn"} ○ Maintenance \<8 wkMaintain normal dose (For details, see manufacturer recommendations)[^9][^10][^11]

The below tables are some examples of different schedules for dose adjustment after gaps in subcutaneous allergen immunotherapy administration, developed by academia, large practices, and guidelines in an attempt to minimize the possibility of a systemic reaction. However, avoidance of a reaction cannot be guaranteed. The physician is further guided in the exact dose adjustment decision by clinical data such as the concentration of allergen being given, previous reaction history, and seasonality.
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[^1]: Abbreviations: AAAAI, American Academy of Allergy, Asthma, and Immunology; SCIT, subcutaneous allergen immunotherapy.

[^2]: Special caution might be needed for the following: (1) history of anaphylaxis or mast cell disorder; (2) moderate to severe asthma; (3) high sensitization pattern or systemic reaction during skin prick testing; (4) systemic reactions to previous SCIT administration; (5) patients receiving SCIT during peak pollen season for an allergen to which they are highly sensitized; and (6) pediatric patients.

[^3]: Abbreviation: SCIT, subcutaneous allergen immunotherapy.

[^4]: Abbreviation: MD, doctor of medicine.

[^5]: NOTE: Normal dosing of vials 1:10,000 and 1:1000 is with 0.10 mL increments, 1:100 and 1:10 with 0.05 increments, and 1:1 with 0.03 increments.

[^6]: Abbreviation: IT, immunotherapy; SCIT, subcutaneous allergen immunotherapy.

[^7]: If on weekly build-up, then it would be up to 14 days after administered injection or 7 days after the missed scheduled injection.

[^8]: Then increase dose each injection visit as directed on the immunotherapy schedule until the therapeutic maintenance dose is reached.

[^9]: Abbreviations: AIT, allergen immunotherapy; SCIT, subcutaneous allergen immunotherapy.

[^10]: Based on the experience of approximately 1000 allergist members of the American Academy of Allergy, Asthma, and Immunology. Adapted from Larenas-Linnemann DE, Gupta P, Mithani S, Ponda P. Survey on immunotherapy practice patterns: dose, dose adjustments, and duration. *Ann Allergy Asthma Immunol*. 2012;108(5):373-378.e3.

[^11]: Preferably continue normally or suspend. It is debatable whether reducing the AIT dose of European extracts results in loss of efficacy.
